Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkers
Sophia Weiner(Institute of Neurobiology), Johan Gobom(Sahlgrenska University Hospital), Kaj Blennow(Sahlgrenska University Hospital), Pieter Jelle Visser(Karolinska Institutet), Betty M. Tijms(Amsterdam Neuroscience), Mathias Sauer(Sahlgrenska University Hospital), Henrik Zetterberg(University of Wisconsin–Madison), Egor Vorontsov(University of Gothenburg)
Cited by 30
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k